News Hub | News Direct

Communications

Advertising Communications Graphic Design Internet Marketing Media Publishing SEO
Article thumbnail News Release

A Nuclear Renaissance Is Reviving Long Stagnant Uranium Markets – Sprott ETFs Is Giving Investors Multiple Forms Of Exposure To The Heavy Metal

Benzinga

By Rachael Green, Benzinga Uranium is one of the latest metals to see its price surge on clean energy demand. The key fuel in nuclear power plants had been declining for decades, but a recent renewed interest in nuclear power as a clean energy source to help economies transition to a fossil fuel-free future has revived investor interest. Uranium prices are up more than 19% since the start of the year as of this writing, trading above $58 per pound in August – the highest it’s been since April of last year, according to data from Trading Economics. Nuclear Power Is The Not-So-New Clean Energy Rising Star The recent surge in uranium prices has been driven largely by recent policy shifts that have made nuclear energy a higher priority as nations work to meet sustainability goals as quickly as possible. Earlier in August, for example, Sweden said it needs to triple its nuclear power capacity over the next decade in order to keep up with rising electricity demand in the country. In the United States, tax credits and investment initiatives in last year’s Inflation Reduction Act have clearly indicated the renewed focus on nuclear energy in the country. Joining Sweden are the UK, Canada, Japan and France which have each announced plans to ramp up uranium supply in efforts to reduce the world’s dependency on Russian uranium. The news has made some investors wonder why all the sudden interest in nuclear energy is cropping up now. But those in the industry are saying it’s actually always been here. “Nuclear is one of those silent contributors,” said Nuclear Energy Institute’s Director of Markets and Policy Benton Arnett in a recent episode of Sprott Radio. “A lot of folks don’t realize it’s producing 20% of our national electricity consumption here in the U.S. and has been doing that very quietly for decades.” It’s a similar story in other countries renewing their focus on nuclear. The reason it’s captured so much attention now is precisely because it’s already fairly well established in the countries that are reinvesting in it. “It is the largest carbon-free generator of power in the [United States.],” Arnett said. As the impacts of climate change have spurred a sense of urgency in the clean energy transition, nations are looking for a faster path away from fossil fuels. While renewables like wind and solar are still key in the long term, nuclear is the energy source that’s already providing a large quantity of clean power for many around the globe. Scaling that up would be a faster solution than building new renewable capacity from scratch. Scaling Up Nuclear Could Push Uranium Into A Supply-Demand Crunch As nations around the globe build new nuclear power plants, uranium – the key fuel supply needed for nuclear energy – is seeing record spikes in demand. In fact, the world’s existing uranium mines were already falling short of demand even before that demand spiked. According to the World Nuclear Association, production in recent years has only met 90% of current nuclear power plant needs. “The number that we’re focused on is trying to hit 150 million pounds or more,” said Sprott Asset Management CEO John Ciampaglia in a Bloor Street Capital interview. “That’s what we think is the annual replacement rate for the world’s existing nuclear power plants.” Getting to that target replacement rate will mean new investments from miners in the exploration and development of new uranium mines, a process that typically takes years. In the meantime, uranium prices could keep shooting higher as growing demand quickly outpaces the capacity of existing uranium mines. Sprott Offers Four Ways To Trade Bullish Uranium Assumptions Sprott has been a leader in precious metals – investing for decades – so expanding into energy transition themes was a natural fit as uranium, lithium, nickel and other metals have become key to so many clean energy projects. The company currently offers four funds for investors who are bullish on uranium and want to gain exposure to the growing market: Sprott Uranium Miners ETF (NYSEARCA: URNM), Sprott Junior Uranium Miners ETF (NASDAQ: URNJ), Sprott Energy Transition Materials ETF (NASDAQ: SETM), and the Sprott Physical Uranium Trust. The first two are focused on uranium miners. While these stocks have felt the pressure of rising interest rates and the high costs of investing in new exploration and development activity, they’ve still managed to pull off healthy gains of over 9% year-to-date, as of this writing. Juniors, meanwhile, climbed nearly 12% in the three-month period ending in July – though they’re still down slightly since the start of the year. Likewise, shares of URNM have rallied 26% since June as of this writing while Sprott’s juniors ETF soared 35% in the same period. The Physical Uranium Trust is the world’s largest physical uranium fund — it “invests and holds substantially all of its assets in uranium in the form of U3O8”, with the goal of providing “a secure, convenient and exchange-traded investment alternative for investors interested in holding uranium.” SETM provides pure-play access to a range of critical minerals necessary for the global clean energy transition including uranium. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 20, 2023 09:00 AM Eastern Daylight Time

Article thumbnail News Release

After $8.8 Million IPO, Hanryu Rolls Out Multiple Revenue-Generating Upgrades To FANTOO, The Fandom App Connecting The Growing Global Audience Of K-Culture Fans

Benzinga

By Rachael Green, Benzinga Hanryu Holdings, Inc. (NASDAQ: HRYU) has had an eventful few weeks after its IPO closed last month, generating about $8.8 million in gross proceeds. In total, the company has raised approximately $53million over multiple fundraising rounds to date as its popular fandom social media app FANTOO grows to a user base of over 26 million and the company unveils a series of upgrades and new features slated to roll out in the coming months. Here’s a look at some of the milestones from the past month and how Hanryu is leveraging those to add new revenue potential to its popular fandom app. What Is FANTOO? Hanryu first launched FANTOO in 2021 as an all-in-one social media platform for K-culture fans worldwide. As K-pop, K-dramas and other forms of entertainment from South Korea continue to gain a growing international audience, there still hasn’t been a single dedicated destination so far where fans could go for any and all fandoms they are part of. Moreover, language barriers were a major hurdle preventing people with a shared fandom from connecting over the music, show or film that they love. FANTOO – with its real-time translation technology across 17 languages and features that allow users to create or join clubs built around any fandom – finally created a way to unify this global audience in one platform. For fans, it’s a way to find community and friendship even if they live somewhere with few other K-culture fans nearby. For Hanryu, it’s an exciting revenue opportunity with the massive advertising potential of a site with millions of dedicated fans. But advertising is just one of the revenue channels Hanryu is building through the platform. It also generates revenue from ticket sales to live shows and transaction fees on the buying and selling that happen in the eBay -like (NASDAQ: EBAY) shop section of FANTOO. The Future Of FANTOO Just days after the closing of its IPO, Hanryu announced the launch of version 2.0 of FANTOO. The upgraded app adds powerful data analytics to help deliver personalized content based on interest settings and the communities in which a user is engaged. It also makes a few updates to the interface to make it more user-friendly and intuitive. “Version 2.0 is also a more robust platform for revenue generation through multiple streams,” said Hanryu CEO Kang Chang Hyeok. “We look forward to releasing additional features and system improvements in the future." One of those future improvements is an AI-powered conversational virtual assistant. Later in August, Hanryu announced that it had partnered with Saltlux Inc. (KOSDAQ: 304100), the company behind Talkbot, an intelligent chatbot. Together, the companies will develop a virtual assistant for FANTOO built on technology similar to Talkbot that can guide users through the platform, make recommendations based on users’ interests and deliver personalized news and updates about their fandom. Slated to launch before the end of this year, the FANTOO virtual assistant is just the beginning. Later, Hanryu plans to use AI voice synthesis and deep learning tech to let users customize the voice of their virtual assistant to sound like their favorite artist or actor – or even themselves. Earlier this month, Hanryu teased even more new chat features coming to the app soon, including emoji purchasing, friend recommendations and club chat rooms where members can join in on club-wide conversations with like-minded fans from around the world – all with the convenience of real-time multilingual translation. A similar open chat room will give users a way to connect with users from other fandoms as well. Alongside the new chat room features, FANTOO will also soon have enhanced private chats where users can talk over an encrypted channel as well as video call functionality so fans who connect through the app can have “face-to-face” conversations with each other. “FANTOO is not just a space for fandom, but it is a place for fans with the same interests to meet and form relationships through chatting,” Hyeok said. “We expect these additional new features, including both the current and planned future upgrades, will increase revenue generation through FANTOO." This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 20, 2023 09:00 AM Eastern Daylight Time

Article thumbnail News Release

The Most Important Things Everyone Should Know Before Investing In Gold IRAs

Benzinga

By Faith Ashmore, Benzinga When it comes to planning for a secure retirement, it is essential to explore all available avenues. Traditional investment options like stocks and bonds have their merits, but there is another store of value that often goes overlooked – gold Individual Retirement Accounts (IRAs). A gold IRA is a type of self-directed retirement account where the holder invests in physical gold instead of conventional assets such as stocks, bonds or mutual funds. Here are five things you need to know about gold IRAs. Harnessing Tax Advantages For Optimal Gains One of the most significant advantages of gold IRAs lies in the attractive tax benefits they offer. Depending on the type of gold IRA you open, you can enjoy favorable tax treatment either during the contribution phase or when you eventually withdraw your funds. For traditional IRAs and Simple Employee Pension (SEP) IRAs, contributions are not taxed, providing an immediate advantage for investors. In contrast, Roth IRAs tax contributions but offer the promise of tax-free withdrawals. Additionally, traditional and SEP IRA contributions are tax-deductible, further enhancing their appeal to investors seeking to maximize their gains. Shielding Your Assets From The Ravages of Inflation In times of economic uncertainty, where the value of the dollar can fluctuate unpredictably, gold presents a historically reliable hedge against inflation. History has shown that gold prices tend to rise when the dollar's value declines, making it an attractive long-term investment. Gold values have proven resilient against interest rate fluctuations, offering stability and solid returns. By incorporating gold into your retirement portfolio through a gold IRA, you can shield your portfolio from the erosive effects of inflation, ensuring that your wealth retains its value over time. A Safe Harbor Amidst Market Turmoil? In today's fast-paced and interconnected world, financial markets are prone to sudden swings and unexpected turbulence. Stock and bond investments can be particularly vulnerable, experiencing significant volatility during economic downturns. However, gold prices have historically displayed a tendency to hold steady during periods of economic turmoil, making gold IRAs an oasis of stability in an uncertain landscape. Strategic Diversification For Sustainable Returns Many experts say the key to successful investing lies in building a well-diversified portfolio, leveraging the strengths and advantages of different asset classes. While high-risk, high-reward investments have their place, a prudent and balanced approach is essential. Gold, as a more conservative asset, plays a crucial role in creating a diversified investment portfolio. While gold very often won’t witness rapid appreciation, the metal is effective at mitigating risk and enhancing stability – preventing extreme losses during turbulent market conditions. By incorporating gold IRAs into your investment strategy, you can strike the optimal balance between growth and security, multiplying the potential for sustainable returns. Choosing The Right Gold IRA Firm – An Option To Consider One leading IRA worth considering is offered by Preserve Gold, a U.S.-based precious metals firm with 0 BBB complaints and excellent reviews. The company specializes in helping individuals and families diversify and protect their wealth through tangible precious metals. The firm provides a selection of gold, silver, platinum, and palladium coins and bars. Preserve Gold distinguishes itself through its focus on three core principles: integrity, transparency and consistency. These principles serve as the company’s foundation for long-lasting customer relationships and reinforce the company's commitment to providing trustworthy and reliable services. To ensure a smooth and secure purchasing process, Preserve Gold offers an informed and easy way to acquire precious metals. The company's knowledgeable team assists clients in making educated purchasing decisions while prioritizing security and ease of transaction. A gold IRA can be an excellent addition to a retirement portfolio. It offers numerous benefits that can help you protect and grow your savings over time. When deciding to invest in a gold IRA, having a trusted partner like Preserve Gold is key to achieving your financial goals. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 20, 2023 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Has ARKK Been Oversold? Traders Are Doubling Down On A Potential Innovation Recovery With This Leveraged ETF

Benzinga

By Rachael Green, Benzinga ARK Innovation ETF (NYSEARCA: ARKK) was an investor darling in the first year of the pandemic with its robust portfolio of COVID-era winners like Zoom (NASDAQ: ZM). But the disruptive tech ETF took a beating in 2022, falling more than 67% throughout the year. However, this year, ARKK seems to have begun a slow and arduous recovery, gaining over 40% year-to-date despite a widespread selloff this summer. Still, it’s far from its 2020 peak of over $150 per share, and some bullish investors believe the partial recovery this year is a sign that the ETF is ready to regain its former glory. Here’s what’s behind that bullish outlook. A Potential Upcoming Pause In Rate Hikes As Economic Data Gives Cause For Optimism Investors remain optimistic that the Federal Reserve will pause interest rate hikes at its upcoming meeting on September 20. In August, key economic indicators were largely mixed but still suggested that inflation was cooling overall. While consumer prices rose from 3% in June to 3.2% in July, core inflation – consumer prices with food and energy prices stripped out– declined slightly from 4.8% in June to 4.7%. And it’s that core inflation that the Federal Reserve wants to see come down to its 2% target. If interest rate hikes are paused, the macroeconomic tailwind this month could add more lift to ARKK which has already begun recovering some of its August losses. Despite Investor Exodus, ARKK Still Has A Potentially Promising Growth Portfolio ARKK may have missed the explosive AI-generated growth of Nvidia (NASDAQ: NVDA), but the top 10 holdings are dotted with underdog growth stocks. For example, the app and game developer platform Unity Software (NYSE: U) just landed a deal this summer to use Unity’s gaming software in Apple’s (NASDAQ: AAPL) upcoming virtual reality headset, Apple Vision Pro. Zoom, the video communications platform that’s been relatively neglected by investors after its pandemic-era boom, has been building up a stockpile of cash that now sits at about $6 billion. It’s planning to use that to grow its enterprise vertical, one of its most successful segments. It’s also spending some of that on new AI-enhanced features, like the new AI Companion, a built-in AI-powered assistant that can catch you up on meetings if you’re late, auto-generate meeting summaries, and even give you feedback on your conversational and presenting skills. You Can Potentially Magnify Your Bullish ARKK Views With the AXS 2X Innovation ETF For investors who see the summer tumble as a hiccup in ARKK’s overall upward trajectory, AXS Investments has designed a unique leveraged ETF just for you. The AXS 2X Innovation ETF (TARK) seeks 200% of the daily performance of the ARK Innovation ETF. That 2x leverage gives investors a chance to turn the ETF’s slow and rocky recovery into more substantial gains. That added leverage does increase the risk of using TARK, so it’s important to use it for short-term trades, such as the potential upswing following the Fed’s upcoming meeting. But when used carefully, TARK is a useful tool for traders who are staunchly bullish on disruptive tech and see the periodic panicked selloffs as an opportunity to find yield. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 20, 2023 09:00 AM Eastern Daylight Time

Article thumbnail News Release

News Direct Announces SYNTHESIS, a Bundled Offering of its Expanding Suite of News and Content Amplification Tools

News Direct

News Direct today announced the launch of News Direct Synthesis, a unique bundling of its evolving suite of digital news and content distribution and amplification services that has expanded from a state-of-the-art newswire offering to include sponsored content posting as well as podcast and streaming TV interview opportunities. Synthesis represents News Direct’s transformation into a single source, multichannel message amplification provider for public relations, investor relations and content marketing professionals. The offering combines its newswire distribution – which includes the ability to distribute standalone digital formats such as video – with sponsored content guest posting via its Idea Marketplace product, along with guest appearance opportunities on News Directly with Steve Hutt, a podcast series that is part of its recently launched News Direct Podcast Channel and News Direct Insights, a joint partnership with Fintech.TV in which senior executives can be interviewed on the streaming channel from the floor of the New York Stock Exchange. The services can be purchased in multiple combinations, providing an opportunity for companies to communicate unified messages using a variety of both “push” and “pull” media and audience targeting strategies and technologies. Gregg Castano, News Direct founder and CEO stated, “Since our launch in 2020, News Direct has consistently been focused on becoming a single destination platform from which PR, IR and marketing professionals could communicate with target audiences via a multitude of digitally enabled engagement tools. Synthesis helps us realize that vision by giving communicators numerous options to engage those audiences via their information technologies of choice. But this is not the end of the journey, rather only the beginning of it. Stay tuned.” About News Direct News Direct is a technology-driven content distribution and amplification platform for PR, IR, corporate communications and marketing professionals. Our automated platform delivers a completely reimagined, modernized user experience for newswire users that has reshaped the industry landscape. Additionally, the company has expanded its offerings to include an array of technology- enhanced message amplification tools ranging from sponsored content to podcasting products, all from one online destination. Contact Details Media Relations +1 203-295-7566 media@newsdirect.com Company Website http://www.newsdirect.com

September 20, 2023 08:33 AM Eastern Daylight Time

Image
Article thumbnail News Release

Bango reports strong first half and expects "spike in profitability" during H2

Bango PLC

Bango PLC (AIM:BGO, OTCQX:BGOPF) chief executive Paul Larbey speaks to Thomas Warner from Proactive after the global platform for data-driven commerce released its interim results for the six months to 30 June 2023. Larbey reports a robust first half with an impressive 88% revenue growth, bolstered by the acquisition of Docomo digital and a strategic agreement with NTT Docomo. Noteworthy is Bango's successful partnership with three out of the top five US telcos, positioning them strongly in a lucrative market. He also highlights the flourishing pipeline for what Bango calls the Digital Vending Machine (DVM), and provides an update on the new integrations launched with Amazon during 2023. Bango's technology has been used by telcos and wallet providers to offer Amazon's digital services, including Prime, Prime Video, Amazon Music Unlimited, Audible, and Kindle Unlimited to their customers via the Amazon Fuse partner program, as a bundle with their own first-party services, for over six years. The company also welcomes Darcy Antonellis, an accomplished figure in the entertainment industry, to its board of directors. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 20, 2023 06:06 AM Eastern Daylight Time

Video
Article thumbnail News Release

First Human Clinical Trials Of A Potentially “Game-Changing Broad Spectrum Antiviral” Are Progressing Successfully – Drug Could Treat COVID, RSV And Many Other Respiratory Viruses

Benzinga

By Rachael Green, Benzinga As COVID cases begin to rise again, heralding the beginning of another COVID wave, new variants have appeared leading this wave. EG.5 (“Eris”) is currently in the majority in the U.S.A, but a very different variant, BA.2.86 (“Pirola”) is already rising in the number of cases. BA.2.86 carries more than 30 changes in its spike protein, as well as changes in other proteins. Scientists believe it is questionable whether the newest booster vaccine shots would be effective for this one. The newest vaccines are “single-agent” targeting the XBB variant. It is not known how effective the approved drugs (mainly Paxlovid - Pfizer Inc. (NYSE: PFE)) would be against this new variant, and further on, as the virus keeps changing. It is now clear that the SARS-CoV-2 virus is here to stay, and that it will keep changing as it continues to learn to avoid vaccines and antibodies and our own immune systems and continues to learn to resist existing old-fashioned drugs. Even without new variants, for clinically vulnerable patients COVID has always continued to be a terrifying reality. In light of this, the broad-spectrum antiviral that is based on a novel nanomedicines platform being developed by one emerging drug company could be promising. NanoViricides, Inc (NYSE American: NNVC ) announced that it has made progress on its Phase 1a/1b clinical trial of NV-CoV-2, a novel antiviral drug candidate that has the potential to treat all strains of the coronavirus. The clinical-stage biotech reported that the safety and tolerability parts of the trial testing the antiviral in healthy subjects is nearly complete and it’s now preparing for the efficacy and dose optimization part of the trial with COVID patients. NanoViricides Broad Spectrum Antiviral Could Change How We Treat Viral Infections So far, NanoViricides has built a robust foundation of promising preclinical research that demonstrates the unique antiviral platform’s potential to treat not just COVID-19 but a wide range of other common and hard-to-treat viral diseases like other coronaviruses, RSV, shingles, herpes, rabies and the flu. The reason it could have such broad applicability is because the NanoViricides platform was specifically designed to target a particular binding site that’s common across many viruses and doesn’t change even as a virus mutates. Essentially, the nanoviricide platform mimics the binding site on a human cell that a virus would normally target in order to infect that cell. Then it seeks out the virus and when the virus binds to the nanoviricide instead, the drug candidate immediately engulfs the virus, where it’s unable to infect the patient’s cells or reproduce. The First Of These Drugs Is Now In Human Phase 1a And 1b Clinical Trials The Phase 1a/1b clinical trial includes single-ascending dose (SAD) and multiple-ascending dose (MAD) safety and tolerability studies in healthy subjects. NanoViricides reported that 26 of the 36 volunteers in the SAD study and 17 of the 36 volunteers in the MAD study have already completed the program. And so far, the early data looks promising. Neither adverse events nor serious adverse events have been found to date in either study. "The excellent safety and tolerability of NV-CoV-2 in both formulations in the clinical trials is consistent with the results of pre-clinical animal studies, giving us confidence that our preclinical animal studies can be expected to be predictive of human clinical trials,” said NanoViricides Executive Chairman and President, Anil R. Diwan, Ph.D. Ongoing Phase 1a And 1b Clinical Trials Will Give First Indication Of Nanoviricides Efficacy In Humans With that baseline of safety and tolerability, the next part of the trial is to enroll COVID patients in the trial and start evaluating whether the positive preclinical effectiveness results for the drug will translate to human trials. Once this trial is finished, NanoViricides plans to seek permission to move into phase 2 clinical trials from multiple regulatory agencies worldwide. Of note, the same drug was found to be effective in pre-clinical studies against another important respiratory virus, RSV. Such a broad spectrum antiviral effectiveness is reminiscent of the development of antibiotics against bacteria. This could be a game-changing development in antiviral therapeutics. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 19, 2023 09:25 AM Eastern Daylight Time

Article thumbnail News Release

B2B Video Visibility & Monetization Platform VideoXRM’s Beta Launch Surpasses 5,000 Video Uploads; Expands Content Sourcing and Audience Engagement with Launch of “Company Advocate”

VideoXRM

VideoXRM, the pioneering B2B video platform that utilizes precise subject indexing and granular search capabilities to drive greater return on investment from video assets, announced today that its Beta launch has surpassed 5,000 video uploads to its platform from a growing base of companies. VideoXRM also announced the launch of its “Company Advocate” functionality to accelerate the growth of its video library through expanded audience engagement. There is no cost to upload or search for content on VideoXRM. The VideoXRM platform provides 75 search parameters including 25 different video/audio characteristics to identify and index the unique attributes of each video, including subject, industry, specialty, participants, roles, geography, corporate status, management, etc. “Company Advocate” VideoXRM’s new “Company Advocate” functionality enables business content creators, customers, partners, media outlets or fans to upload content on behalf of a company. This new feature is designed to expand the reach, engagement, and growth of content on the VideoXRM platform. David Baker, VideoXRM’s Founder and CEO, commented, “We are excited by the growing engagement and constructive customer comments and suggestions we have gained through our Beta launch. This feedback loop has already contributed to new features such as the ‘Company Advocate’ functionality that substantially expands potential content sources and value for our platform.” VideoXRM brings the “X factor” to Customer Relationship Management (CRM) by expanding it ALL stakeholders including partners, constituents, employees, analysts, suppliers, researchers, recruiters, marketers, journalists, investors, citizens, bankers, etc. Given the growing user preference for video and rich media, VideoXRM provides a powerful new medium for exposure and precise searches. About VideoXRM ( VideoXRM.com ) VideoXRM is a global, searchable video and audio sharing and networking platform connecting corporate rich media content with all potential stakeholders. The platform and smart search technology creates value and knowledge from mountains of unstructured digital media, delivering greater ROI from content investments. VideoXRM’s mission is harnessing the enhanced communicative power of rich media through a new distribution and discovery paradigm. VideoXRM was Co-founded by David N. Baker, who formed Revere Data LLC (Sectorbase) which was acquired by FactSet Data Systems, Inc. His Co-founders are Vadim A. Tarasov, Byron Kwok, and David Guzy. Connect with us on LinkedIn and Twitter and Facebook. Contact Details Catalyst IR David C. Collins +1 212-924-9800 videoxrm@catalyst-ir.com Company Website https://videoxrm.com

September 19, 2023 08:55 AM Eastern Daylight Time

Article thumbnail News Release

September is Cholesterol Education Month

YourUpdateTV

September is Cholesterol Education Month and for people with unsafe levels of high LDL (bad) cholesterol, there are many options in the treatment toolbox. Recently, Preventive Cardiologist Dr. Seth Baum participated in a nationwide satellite media tour to discuss high LDL cholesterol, best treatment options, and tips for patients navigating challenges with their health coverage. A video accompanying this announcement is available at: https://youtu.be/rcUk4OWkpD4 Heart disease remains the leading cause of death in the United States and LDL-cholesterol, what we call the “bad” cholesterol, is a major risk factor which can lead to a heart attack or a stroke. While many can lower their LDL cholesterol with a heart healthy diet, some will need medication to reach their Safe Zone. Statins are often the first-line of treatment for individuals with high LDL cholesterol, not all patients reach their recommended LDL cholesterol levels with statins alone. In these cases, lipid-lowering medications, known as PCSK9 inhibitors, are often recommended to help lower cholesterol levels. Unfortunately, individuals who are prescribed PCSK9 inhibitors are facing significant hurdles in accessing and using these potentially life-saving drugs, despite their proven efficacy in reducing LDL cholesterol. One major obstacle is insurance company denials or rejections. Data published in the November 2022 Journal of the American Medical Association found that for commercially insured patients prescribed a PCSK9 inhibitor, only 42% of initial rejections were overturned. Sadly, nearly 75% of patients rejected for a PCSK9 inhibitor ended up on no therapy, which is not a win for anyone. Research from the Family Heart Foundation shows that compared to individuals who were able to obtain their prescribed PCSK9 inhibitor, those whose prescription was rejected or abandoned experienced more heart attacks, strokes, and other cardiovascular events within 12 months. For more information and resources that can help, visit LDLSafeZone.org About Seth Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC Dr. Seth J. Baum is Chief Scientific Officer at Flourish Research, and clinical affiliate professor of Cardiology at FAU Medical School. He actively consults in Clinical Lipidology and Cardiovascular Disease Prevention and continues to offer lipoprotein apheresis for patients in southeast and central Florida. Dr. Baum has practiced Preventive Cardiology and Clinical Lipidology since 2000. He is a fellow of the American College of Cardiology, the American Heart Association, the American College of Preventive Medicine, the National Lipid Association, and the American Society for Preventive Cardiology. Dr. Baum is a past President of the American Society for Preventive Cardiology (ASPC). He currently serves on both the ASPC and Family Heart Foundation Advisory Boards. He has published over 100 peer reviewed papers and abstracts as well as two books. In 2013, he was awarded Cleveland Heart Lab’s “Heart Award” for lifelong dedication to Preventive Medicine. In 2019, Dr. Baum received Mended Hearts’ biennial Dwight Emary Harken Award. Dr. Baum is the Founder of Excel Medical Clinical Trials, LLC, a consortium of clinicians dedicated to the safe and professional conduct of high-level scientific trials. He has served as Principal Investigator in over 100 clinical trials covering a broad range of disease states. Dr. Baum is the Chief Scientific Officer of Flourish Research, a leading national clinical research company. Dr. Baum is a graduate of Columbia College and Columbia College of Physicians and Surgeons, and completed training in Internal Medicine, Cardiology, Interventional Cardiology, and Electrophysiology Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

September 18, 2023 10:27 AM Eastern Daylight Time

Video
1 ... 7374757677 ... 262